Structure Therapeutics (GPCR) is a clinical-stage biopharma company that went public in 2023. Valued at $1.7 billion by market cap, Structure Therapeutics is focused on developing oral treatments for chronic metabolic and cardiopulmonary conditions. It utilizes a structure-based drug discovery platform, allowing the company to establish a G-protein coupled receptors (GPCR) targeted pipelines, that features two clinical-stage small molecule compounds designed to surpass limitations associated with traditional biologic and peptide therapies.
Today, GPCR stock trades roughly 50% below all-time highs, allowing you to buy the dip. Let’s see why Wall Street is bullish on this healthcare stock in 2024.
